Hartmann Katherine, Gillman Jennifer A, Lazor Jillian W, Ware Jeffrey B, Weeks Joanna K, Nasrallah Ilya M, Farwell Michael D, Pantel Austin R
From the Department of Radiology, Hospital of the University of Pennsylvania, Pennsylvania, PA.
Mid-Atlantic Permanente Medical Group, Rockville, MD.
Clin Nucl Med. 2024 Jan 1;49(1):9-15. doi: 10.1097/RLU.0000000000004966. Epub 2023 Dec 1.
The differentiation of paragangliomas, schwannomas, meningiomas, and other neuroaxis tumors in the head and neck remains difficult when conventional MRI is inconclusive. This study assesses the utility of 68 Ga-DOTATATE PET/CT as an adjunct to hone the diagnosis.
This retrospective study considered 70 neuroaxis lesions in 52 patients with 68 Ga-DOTATATE PET/CT examinations; 22 lesions (31%) had pathologic confirmation. Lesions were grouped based on pathological diagnosis and best radiologic diagnosis when pathology was not available. Wilcoxon rank sum tests were used to test for differences in SUV max among paragangliomas, schwannomas, and meningiomas. Receiver operator characteristic curves were constructed.
Paragangliomas had a significantly greater 68 Ga-DOTATATE uptake (median SUV max , 62; interquartile range [IQR], 89) than nonparagangliomas. Schwannomas had near-zero 68 Ga-DOTATATE uptake (median SUV max , 2; IQR, 1). Intermediate 68 Ga-DOTATATE uptake was seen for meningiomas (median SUV max , 19; IQR, 6) and other neuroaxis lesions (median SUV max , 7; IQR, 9). Receiver operator characteristic analysis demonstrated an area under the curve of 0.87 for paragangliomas versus all other lesions and 0.97 for schwannomas versus all other lesions.
Marked 68 Ga-DOTATATE uptake (>50 SUV max ) favors a diagnosis of paraganglioma, although paragangliomas exhibit a wide variability of uptake. Low to moderate level 68 Ga-DOTATATE uptake is nonspecific and may represent diverse pathophysiology including paraganglioma, meningioma, and other neuroaxis tumors but essentially excludes schwannomas, which exhibited virtually no uptake.
当传统MRI检查结果不明确时,头颈部副神经节瘤、神经鞘瘤、脑膜瘤及其他神经轴肿瘤的鉴别诊断仍存在困难。本研究评估⁶⁸Ga-DOTATATE PET/CT作为辅助手段以优化诊断的效用。
本回顾性研究纳入了52例接受⁶⁸Ga-DOTATATE PET/CT检查的患者的70处神经轴病变;其中22处病变(31%)有病理证实。病变根据病理诊断进行分组,若无法获得病理结果,则根据最佳影像学诊断进行分组。采用Wilcoxon秩和检验来检测副神经节瘤、神经鞘瘤和脑膜瘤之间最大标准摄取值(SUV max)的差异。构建了受试者工作特征曲线。
副神经节瘤对⁶⁸Ga-DOTATATE的摄取显著高于非副神经节瘤(SUV max中位数为62;四分位数间距[IQR]为89)。神经鞘瘤对⁶⁸Ga-DOTATATE的摄取几乎为零(SUV max中位数为2;IQR为1)。脑膜瘤(SUV max中位数为19;IQR为6)和其他神经轴病变(SUV max中位数为7;IQR为9)对⁶⁸Ga-DOTATATE的摄取处于中等水平。受试者工作特征分析显示,副神经节瘤与所有其他病变相比曲线下面积为0.87,神经鞘瘤与所有其他病变相比曲线下面积为0.97。
显著的⁶⁸Ga-DOTATATE摄取(SUV max>50)有助于副神经节瘤的诊断,尽管副神经节瘤的摄取表现出很大的变异性。低至中等水平的⁶⁸Ga-DOTATATE摄取是非特异性的,可能代表多种病理生理情况,包括副神经节瘤、脑膜瘤和其他神经轴肿瘤,但基本上可排除几乎无摄取的神经鞘瘤。